Saint-Herblain (France) and Emeryville (USA), 14 September 2020 – Valneva SE (“Valneva”), a vaccine company aimed at preventing diseases of significant needs not covered, and Dynavax Technologies Corporation (Nasdaq: DVAX), a corporate biopharmaceutical focused on the progression and advertising of new vaccines, today announced an advertising partnership for dynavax’s CpG 1018 adjuvant source to be used in Valne’s candidate vaccine for SARS-CoV-2. VLA2001. Valneva today announced an agreement with the UK government to obtain up to 190 million doses of VLA20011 over a five-year period. Dynavax will get CpG 1018 to produce up to one hundred million doses of vaccine until 2021. Valneva has the option to purchase up to 90 million additional doses until 2025.
Thomas Lingelbach, CEO of Valneva, said: “We are very happy to be a spouse with Dynavax because of the progression and long-term marketing of our COVID-19 vaccine. We believe that CpG 1018 will charge a significant price on the target product profile of our vaccine, adding its intended use in at-risk populations. This agreement marks a new step in our technique to find a safe and effective solution to the virus that continues to have an effect on all of us”.
Ryan Spencer, CEO of Dynavax, commented, “Dynavax is proud to work with Valneva to help the progression and advertising of an adjuvant candidate vaccine to save him COVID-19. We are pleased to expand our existing partnership to include advertising for CpG 1018, our adjuvant community. We believe that CpG 1018 can play a key role in the progression of a safe and effective vaccine, potentially adding to improving the immune reaction of those who are historically less sensitive to vaccination and have the highest threat of severe COVID-19 disease. »
About VLA2001
VLA2001 is an inactivated and purified candidate mobile vero candidate candidate vaccine at the top opposite sarS-CoV-2 virus, taking credit for the technology of producing Japanese valneva encephalitis vaccines. steps like plug-and-play with moderate settings. The procedure involves inactivation with BPL to maintain the local distribution of protein S. Mixing with CpG 1018 is expected to induce a strong immune reaction and have the possibility of generating higher titer neutralizing antibodies as well as a polarized Th1 reaction. VLA2001 is expected to meet the needs of the bloodless chain (2 degrees to 8 degrees Celsius).
Valneva SE Valneva is a vaccine company that focuses on the prevention of diseases with unmet primary needs. Valneva’s portfolio includes two advertising vaccines for travellers: IXIARO® / JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for cholera prevention and, in some countries, the prevention of diarrhoea caused through ETEC. The Society has a variety of vaccines in development, adding exclusive vaccines for Lyme disease, chikungunya and SARS-CoV-2. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the United States with more than 500 employees. For more information, visit the company’s online page at www. valneva. com and stay on Valneva on LinkedIn.
Derek Cole, President investisseursderek. cole@IRadvisory. com Advisory Solutions
1Valneva confirms its participation in the UK government’s COVID-19 vaccine reaction programme
2Valneva and Dynavax announce collaboration to drive COVID-19 vaccine development